Is BioSig for Real This Time With Its Pure EP?

A couple years ago, BioSig Technologies, Inc. was poised to apply for FDA clearance to market its technology to improve treatment of atrial fibrillation and ventricular tachycardia. Then its scientific advisors advised the Minneapolis company to put more work into that technology, a hardware-software combination designed to present clearer signals during electrophysiology studies and catheter ablation. The technology, Pure EP, is designed to cut through the background noise of the lab and its equipment during cardiac recordings, enabling physicians to target and neutralize the areas of the heart that are causing atrial fibrillation (Afib), and ventricular tachycardia (VT), according to BioSig. More accurate targeting of the offending tissue may reduce the number of repeat catheter ablation procedures, which can last up to eight hours. AFib is the most common human arrhythmia, affecting about 33 million patients worldwide. Often asymptomatic, it is associated with one-third of all ischemic strokes a well as a risk of heart failure and death. VT can also lead to sudden death. BioSig’s system is designed to remove baseline wander, noise and artifacts, which make it difficult for physicians to see true cardiac signals. Baseline wander causes cardiac signals to shift from the isoelectric line. Signals that come from the patient’s body and the recording environment can produce noise that masks fine cardiac signal.  And artifacts can intrude on those signals from a patient’...
Source: MDDI - Category: Medical Devices Authors: Tags: MD & M Minneapolis R Software Source Type: news